Eli Lilly and Company’s LLY shares have lost 17% so far in May. Lilly announced mixed earnings results on May 1. It missed ...

Shares of Eli Lilly fell sharply Thursday morning after the pharmaceutical giant's lowered profit projections outweighed ...

Please go ahead. Good morning. Thank you for joining us for Eli Lilly company's Q1 2025 Earnings Call. I'm Mike Czapar, Senior Vice President of Investor Relations. Joining me on today's call are ...

Eli Lilly reports 1Q earnings on Thursday, with EPS of $3.05 and revenues of $12.67 billion expected. Stock is up 14.35% in past year.

Leading me to believe Eli Lilly is likely to beat estimates in Q1 2025 earnings while potentially lowering FY 2025 revenue guidance, accounting for the negative impact of multiple headwinds.

Shares of Eli Lilly ( LLY -5.50%) are sliding on Thursday. The stock lost 8.3% as of 12:21 p.m. ET. The leg down comes as the ...

I had a chance to speak to Eli Lilly's CEO, David Ricks, and he told me that on the news of this deal, you know, the company isn't really looking at it. He said it feels a little bit like last decade.

LLY has delivered impressive returns of 15% year-to-date (as of April 30), outperforming the S&P 500’s 5% decline during the same period. This investor optimism stems from massive demand for the ...

Eli Lilly (NYSE: NYSE:LLY ... management's commentary on any changes to full-year EPS and revenue guidance and Q1 prescription trends for Mounjaro, Zepbound, and pipeline assets.